Home Tags IMMU-132

Tag: IMMU-132

Breakthrough Therapy Designation for Sacituzumab Govitecan in Triple-negative Breast Cancer

Sacituzumab govitecan, also known as IMMU-132, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients...

Sacituzumab govitecan (IMMU-132) Shows Positive Interim Phase II Results

Sacituzumab govitecan also known as IMMU-132, an antibody-drug conjugate being developed by Immunomedics, a clinical-stage biopharmaceutical company, continues to produce durable responses in patients with...

ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers

With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...

New Data on Novel ADC For Solid Cancer Presented at Joint...

Clinical data on IMMU-132, an anti-TROP-2-SN-38 Anitbody-drug Conjugate currently being evaluated in patients with solid tumors, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and...

X